HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces it has dosed the first subject in a Phase 1 trial evaluating its novel EP4 receptor agonist, HTL0033744 (HTL’744) for the treatment of Inflammatory Bowel Disease (IBD), a therapeutic area where there remains significant unmet need for millions of people worldwide.

HTL0033744由Sosei Heptares设计，用于促进日本东京和英国剑桥IBD患者的粘膜愈合和解决炎症，2024年3月21日-Sosei Group Corporation（“Sosei Heptares”或“the Company”；TSE:4565）宣布，它已经在一期试验中给药，该试验评估了其新型EP4受体激动剂HTL0033744（HTL'744），用于治疗炎症性肠病（IBD），这是一个治疗领域，全球数百万人仍然有大量未满足的需求。

HTL’744 is a potent, selective and gut-restricted prostaglandin EP4 receptor agonist that has been uniquely designed to bring clinical benefit by accelerating the healing of damaged epithelial mucosa and suppressing exaggerated gut inflammation, with minimal systemic exposure to avoid adverse events.

HTL'744是一种有效的，选择性和肠道限制性的前列腺素EP4受体激动剂，经过独特设计，可通过加速受损上皮粘膜的愈合和抑制过度的肠道炎症来带来临床益处，同时尽量减少全身暴露以避免不良事件。

This approach is widely recognized to promote deeper remission and offer better long-term clinical outcomes1,2. HTL’744 aims to address the significant unmet need of people with IBD that do not achieve satisfactory disease control. Current treatments for IBD typically achieve remission rates of less than 25%, and the safety profile of these drugs mean that they require careful monitoring.

这种方法被广泛认可可以促进更深入的缓解，并提供更好的长期临床结果1,2。HTL'744旨在解决IBD患者无法实现令人满意的疾病控制的重大未满足需求。目前治疗IBD的缓解率通常低于25%，这些药物的安全性意味着需要仔细监测。

The Phase 1 trial is a first-in-human randomized, double-blind study to assess the safety, pharmacokinetics and effects on pharmacodynamic biomarkers of single and multiple ascending doses of HTL’744 in adult healthy volunteers and people with Crohn’s disease to generate proof of mechanism. The trial will be conducted in the UK and initial data read-outs are anticipated from 2025.

第一阶段试验是一项首次在人体内进行的随机双盲研究，旨在评估成人健康志愿者和克罗恩病患者单次和多次递增剂量HTL'744的安全性，药代动力学以及对药效学生物标志物的影响，以产生机制证明。该试验将在英国进行，预计从2025年开始读取初始数据。

Matt Barnes, President of Heptares Therapeutics and Head of UK R&D, said: “It’s great to see the progression of HTL’744, another of our wholly owned assets, into the clinic. EP4 agonists are a recognized and e.

Heptares Therapeutics总裁兼英国研发主管马特·巴恩斯（MattBarnes）表示：“很高兴看到我们的另一项全资资产HTL'744进入临床。EP4激动剂是公认的e。